Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chapuis

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Leukemia|October 4, 2017
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodelingG Kerdivel, V Chesnais, E Becht, et al.
Targeted Oncology|July 26, 2015
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanomaN Kramkimel, A Thomas-Schoemann, L Sakji, et al.
Leukemia|June 13, 2008
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AMLS Park, N Chapuis, V Bardet, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|March 11, 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cellsL Poulain, P Sujobert, F Zylbersztejn, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Leukemia|October 4, 2017
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodelingG Kerdivel, V Chesnais, E Becht, et al.
Targeted Oncology|July 26, 2015
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanomaN Kramkimel, A Thomas-Schoemann, L Sakji, et al.
Leukemia|June 13, 2008
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AMLS Park, N Chapuis, V Bardet, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|March 11, 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cellsL Poulain, P Sujobert, F Zylbersztejn, et al.
Pageof 3